Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Education

Biotechnology

Lucy Therapeutics

Amy Ripka

Allen Hopper

Yipeng Du

Vera Procaccia

Minevere Sinani

Robin Grammer

Jessica Garrant

Bryan Keaney

The Research and Development Team at Lucy Therapeutics is dedicated to advancing the company's innovative drug discovery efforts by conducting rigorous experimental studies to validate targets associated with early disease pathogenesis. This team leverages their expertise in mitochondrial function to explore and develop novel therapeutic strategies for CNS diseases such as Rett Syndrome and Parkinson’s, ensuring a focus on disease modification rather than symptom management. Through collaboration and cross-functional research, they aim to establish proof of concept and optimize dosing regimens to enhance neuroprotection and potential clinical outcomes.

Research and Development Team

Scientific Advisors

Leadership Team

Research and Development Team

About

Team members

Other teams at Lucy Therapeutics

Scientific Advisors

Leadership Team